Protara Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Protara Therapeutics details its 2024 financial results and provides updates on its clinical development programs for TARA-002 and IV Choline Chloride.
NASDAQ
Protara Therapeutics, a clinical-stage biopharmaceutical company, released its 2023 annual report, highlighting progress in its TARA-002 and IV Choline Chloride development programs while reporting a net loss.